PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Prevalence of Drug-Resistant Minority Variants in Untreated HIV-1-Infected Individuals With and Those Without Transmitted Drug Resistance Detected by Sanger Sequencing.

Abstract Minority variant human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations are associated with an increased risk of virological failure during treatment with NNRTI-containing regimens. To determine whether individuals to whom variants with isolated NNRTI-associated drug resistance were transmitted are at increased risk of virological failure during treatment with a non-NNRTI-containing regimen, we identified minority variant resistance mutations in 33 individuals with isolated NNRTI-associated transmitted drug resistance and 49 matched controls. We found similar proportions of overall and nucleoside reverse transcriptase inhibitor-associated minority variant resistance mutations in both groups, suggesting that isolated NNRTI-associated transmitted drug resistance may not be a risk factor for virological failure during treatment with a non-NNRTI-containing regimen.
PMID
Related Publications

Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.

Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.

Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.

Minority resistant HIV-1 variants and the response to first-line NNRTI therapy.

Authors

Mayor MeshTerms
Keywords

HIV-1

antiretroviral therapy

drug resistance

minority variant

next-generation sequencing

Journal Title the journal of infectious diseases
Publication Year Start




PMID- 28859436
OWN - NLM
STAT- MEDLINE
DA  - 20170901
DCOM- 20170907
LR  - 20170907
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 216
IP  - 3
DP  - 2017 Aug 01
TI  - Prevalence of Drug-Resistant Minority Variants in Untreated HIV-1-Infected
      Individuals With and Those Without Transmitted Drug Resistance Detected by Sanger
      Sequencing.
PG  - 387-391
LID - 10.1093/infdis/jix338 [doi]
AB  - Minority variant human immunodeficiency virus type 1 (HIV-1) nonnucleoside
      reverse transcriptase inhibitor (NNRTI) resistance mutations are associated with 
      an increased risk of virological failure during treatment with NNRTI-containing
      regimens. To determine whether individuals to whom variants with isolated
      NNRTI-associated drug resistance were transmitted are at increased risk of
      virological failure during treatment with a non-NNRTI-containing regimen, we
      identified minority variant resistance mutations in 33 individuals with isolated 
      NNRTI-associated transmitted drug resistance and 49 matched controls. We found
      similar proportions of overall and nucleoside reverse transcriptase
      inhibitor-associated minority variant resistance mutations in both groups,
      suggesting that isolated NNRTI-associated transmitted drug resistance may not be 
      a risk factor for virological failure during treatment with a
      non-NNRTI-containing regimen.
CI  - (c) The Author 2017. Published by Oxford University Press for the Infectious
      Diseases Society of America. All rights reserved. For permissions, e-mail:
      [email protected]
FAU - Clutter, Dana S
AU  - Clutter DS
AD  - Division of Infectious Diseases and Geographic Medicine.
FAU - Zhou, Shuntai
AU  - Zhou S
AD  - Department of Biochemistry and Biophysics, University of North Carolina-Chapel
      Hill.
FAU - Varghese, Vici
AU  - Varghese V
AD  - Division of Infectious Diseases and Geographic Medicine.
FAU - Rhee, Soo-Yon
AU  - Rhee SY
AD  - Division of Infectious Diseases and Geographic Medicine.
FAU - Pinsky, Benjamin A
AU  - Pinsky BA
AD  - Division of Infectious Diseases and Geographic Medicine.
AD  - Department of Pathology, Stanford University School of Medicine.
FAU - Jeffrey Fessel, W
AU  - Jeffrey Fessel W
AD  - Department of Internal Medicine, San Francisco Medical Center, Kaiser Permanente 
      Northern California,San Francisco.
FAU - Klein, Daniel B
AU  - Klein DB
AD  - Department of Infectious Diseases, San Leandro Medical Center, Kaiser Permanente 
      Northern California,San Leandro.
FAU - Spielvogel, Ean
AU  - Spielvogel E
AD  - Department of Biochemistry and Biophysics, University of North Carolina-Chapel
      Hill.
FAU - Holmes, Susan P
AU  - Holmes SP
AD  - Department of Statistics, Stanford University, Stanford.
FAU - Hurley, Leo B
AU  - Hurley LB
AD  - Division of Research, Kaiser Permanente Northern California, Oakland, California.
FAU - Silverberg, Michael J
AU  - Silverberg MJ
AD  - Division of Research, Kaiser Permanente Northern California, Oakland, California.
FAU - Swanstrom, Ronald
AU  - Swanstrom R
AD  - Department of Biochemistry and Biophysics, University of North Carolina-Chapel
      Hill.
FAU - Shafer, Robert W
AU  - Shafer RW
AD  - Division of Infectious Diseases and Geographic Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Reverse Transcriptase Inhibitors)
SB  - AIM
SB  - IM
MH  - Adult
MH  - CD4 Lymphocyte Count
MH  - Drug Resistance, Viral/*genetics
MH  - Female
MH  - HIV Infections/*drug therapy
MH  - HIV-1/drug effects/*genetics
MH  - Humans
MH  - Male
MH  - Mutation
MH  - Reverse Transcriptase Inhibitors/*therapeutic use
MH  - Sequence Analysis, DNA
OTO - NOTNLM
OT  - HIV-1
OT  - antiretroviral therapy
OT  - drug resistance
OT  - minority variant
OT  - next-generation sequencing
EDAT- 2017/09/02 06:00
MHDA- 2017/09/08 06:00
CRDT- 2017/09/02 06:00
PHST- 2017/05/17 [received]
PHST- 2017/07/17 [accepted]
AID - 4035911 [pii]
AID - 10.1093/infdis/jix338 [doi]
PST - ppublish
SO  - J Infect Dis. 2017 Aug 1;216(3):387-391. doi: 10.1093/infdis/jix338.